CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
This Quarter Return
+9.19%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$709M
AUM Growth
+$709M
(-9.9%)
Cap. Flow
-$72.4M
Cap. Flow
% of AUM
-10.22%
Top 10 Holdings %
Top 10 Hldgs %
37.25%
Holding
452
New
12
Increased
93
Reduced
281
Closed
40
Top Buys
| 1 |
NVIDIA
NVDA
|
$40.6M |
| 2 |
Apple
AAPL
|
$9.08M |
| 3 |
Applied Materials
AMAT
|
$5.39M |
| 4 |
Arista Networks
ANET
|
$5.26M |
| 5 |
Amphenol
APH
|
$5.14M |
Top Sells
| 1 |
Amgen
AMGN
|
$8.02M |
| 2 |
Adobe
ADBE
|
$7.95M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$7.6M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$6.84M |
| 5 |
Lam Research
LRCX
|
$5.23M |
Sector Composition
| 1 | Technology | 43.87% |
| 2 | Healthcare | 22.25% |
| 3 | Consumer Discretionary | 12.69% |
| 4 | Communication Services | 10.44% |
| 5 | Consumer Staples | 3.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
376
Nautilus Biotechnolgy
NAUT
$84.3M
| $34.4K | ﹤0.01% |
14,717
-9,359
| -39% | -$21.9K |
|
377
Zentalis Pharmaceuticals
ZNTL
$125M
| $34.1K | ﹤0.01% |
8,343
-5,291
| -39% | -$21.6K |
|
378
Atea Pharmaceuticals
AVIR
$271M
| $32.7K | ﹤0.01% |
9,894
-6,285
| -39% | -$20.8K |
|
|
AMRN
379
Amarin Corp
AMRN
$317M
| $32.3K | ﹤0.01% |
46,967
-27,211
| -37% | -$18.7K |
|
380
Align Technology
ALGN
$9.95B
| $32.1K | ﹤0.01% |
133
| – | – |
|
381
MeiraGTx Holdings
MGTX
$586M
| $31.8K | ﹤0.01% |
7,556
-4,690
| -38% | -$19.7K |
|
|
RVNC
382
DELISTED
Revance Therapeutics, Inc.
RVNC
| $31.5K | ﹤0.01% |
12,271
-4,710
| -28% | -$12.1K |
|
383
MacroGenics
MGNX
$111M
| $31.3K | ﹤0.01% |
7,357
-4,578
| -38% | -$19.5K |
|
|
EXAI
384
DELISTED
Exscientia Plc American Depositary Shares
EXAI
| $29.4K | ﹤0.01% |
5,755
-3,519
| -38% | -$17.9K |
|
385
uniQure
QURE
$926M
| $28.8K | ﹤0.01% |
6,430
-3,492
| -35% | -$15.6K |
|
386
ATAI Life Sciences
ATAI
$982M
| $26.2K | ﹤0.01% |
19,666
-12,233
| -38% | -$16.3K |
|
387
Deckers Outdoor
DECK
$18.2B
| $24.2K | ﹤0.01% |
25
-650
| -96% | -$629K |
|
388
Edwards Lifesciences
EW
$48.1B
| $23.6K | ﹤0.01% |
256
| – | – |
|
389
Coherus Oncology, Inc. Common Stock
CHRS
$138M
| $23.3K | ﹤0.01% |
13,479
-7,947
| -37% | -$13.7K |
|
|
BLUE
390
DELISTED
bluebird bio
BLUE
| $22K | ﹤0.01% |
22,363
-14,217
| -39% | -$14K |
|
391
Ventyx Biosciences
VTYX
$175M
| $19.1K | ﹤0.01% |
8,282
-3,103
| -27% | -$7.17K |
|
392
Biomea Fusion
BMEA
$122M
| $19K | ﹤0.01% |
4,223
-2,639
| -38% | -$11.9K |
|
393
Charles River Laboratories
CRL
$7.9B
| $18.4K | ﹤0.01% |
89
| – | – |
|
394
IQVIA
IQV
$31.4B
| $17.8K | ﹤0.01% |
84
| – | – |
|
395
Caribou Biosciences
CRBU
$175M
| $17.4K | ﹤0.01% |
10,612
-6,412
| -38% | -$10.5K |
|
396
Amylyx Pharmaceuticals
AMLX
$876M
| $15.2K | ﹤0.01% |
7,990
-5,014
| -39% | -$9.53K |
|
|
ME
397
DELISTED
23andMe Holding Co. Class A Common Stock
ME
| $14.9K | ﹤0.01% |
38,012
-22,641
| -37% | -$8.86K |
|
398
Repligen
RGEN
$6.79B
| $14.5K | ﹤0.01% |
115
| – | – |
|
399
RAPT Therapeutics
RAPT
$198M
| $12.5K | ﹤0.01% |
4,101
-2,501
| -38% | -$7.63K |
|
400
Aclaris Therapeutics
ACRS
$219M
| $9.21K | ﹤0.01% |
8,372
-5,255
| -39% | -$5.78K |
|